Home

Shinkane Pole trochu cd38 marker multiple myeloma Bezchybný dodržování Vybrat

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide

Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen
Immunophenotyping in Multiple Myeloma and Others Monoclonal Gammopathies | IntechOpen

International Clinical Cytometry Society
International Clinical Cytometry Society

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica

KoreaMed Synapse
KoreaMed Synapse

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia

CD38 - Wikipedia
CD38 - Wikipedia

ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines
ePosters - Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell Lines

PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar
PDF] Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma | Semantic Scholar

CD38 expression and function in NK cells. (A) Role of CD38 in the... | Download Scientific Diagram
CD38 expression and function in NK cells. (A) Role of CD38 in the... | Download Scientific Diagram

Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model | Journal of Nuclear Medicine
Comparison of CD38-Targeted α- Versus β-Radionuclide Therapy of Disseminated Multiple Myeloma in an Animal Model | Journal of Nuclear Medicine

International Clinical Cytometry Society
International Clinical Cytometry Society

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica
Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients | Haematologica

Double CD38−/CD138− negative multiple myeloma - ScienceDirect
Double CD38−/CD138− negative multiple myeloma - ScienceDirect

High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action - Adams - 2019 - Cytometry Part A - Wiley Online Library
High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action - Adams - 2019 - Cytometry Part A - Wiley Online Library

Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems
Detect CD38 expression during anti-CD38 therapy – Caltag Medsystems

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab | Leukemia

A Guide to Plasma Cell Markers | Biocompare: The Buyer's Guide for Life Scientists
A Guide to Plasma Cell Markers | Biocompare: The Buyer's Guide for Life Scientists

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance | Semantic Scholar
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance | Semantic Scholar

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma | Journal of Hematology & Oncology | Full Text
In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma | Journal of Hematology & Oncology | Full Text

CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging | Radiology
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging | Radiology

Cureus | Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario | Article
Cureus | Secondary Plasma Cell Leukemia in a Recurrent Multiple Myeloma: Rare Case Scenario | Article

Cureus | CD38: From Positive to Negative Expression after Daratumumab Treatment | Article
Cureus | CD38: From Positive to Negative Expression after Daratumumab Treatment | Article

Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy
Cells | Free Full-Text | The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy

CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma - ScienceDirect
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma - ScienceDirect

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formatio
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formatio